



**FOR IMMEDIATE RELEASE**

**Media Contact:**

Katie Engleman, Pure Communications  
910-509-3977

**Atterocor Announces Data Presentations at ENDO 2015**

**Ann Arbor, Michigan – March 3, 2015** – Atterocor, Inc., a company developing a novel therapy for adrenal cancer, today announced three poster presentations on ATR-101 at ENDO 2015: The Endocrine Society's 97th Annual Meeting & Expo, being held Mar. 5-8 at the San Diego Convention Center in San Diego. ATR-101 is the company's novel, oral drug candidate in a [Phase 1](#) clinical study for the treatment of adrenocortical carcinoma (ACC). ATR-101 is a selective inhibitor of ACAT1, which reduces adrenal steroids and induces apoptosis of cells derived from the adrenal cortex.

"The data being presented at ENDO provides further details on the novel biology of ATR-101 and demonstrates a deeper understanding of its role in treating adrenal diseases," said Julia C. Owens, Ph.D., president and chief executive officer of Atterocor. "In particular, our ongoing collaboration with the lab of Dr. Gary Hammer at the University of Michigan has elucidated detailed mechanistic insights of ATR-101's effects in adrenal cancer cells. We are very encouraged by the profile of ATR-101 seen in a growing body of data to date and look forward to continued development of this treatment with the hope of providing patients with a new therapeutic option in adrenal cancer."

The schedule of ATR-101 poster presentations at ENDO 2015 is as follows:

**Title:** ATR-101, a Selective and Potent Inhibitor of ACAT1, Increases Intracellular Free Cholesterol, ER Stress and Apoptosis in Adrenal Cancer Cells

**Session:** FRI 330-350-Tumorigenesis, Metastasis, and Therapies for Cancer Basic/Translational

**Date/Time:** Friday, Mar. 6, 2015, 1-3:00 p.m.

**Location:** Hall D-F, Tumor Biology

**Poster:** FRI-340

**Presenter:** Christopher R. LaPensee, Ph.D., University of Michigan

**Title:** ATR-101, a Selective ACAT1 Inhibitor, Decreases ACTH-Stimulated Cortisol Levels in Naturally-Occurring Cushing's Syndrome in Dogs

**Session:** FRI 354-376-Adrenal Tumors, Glucocorticoid Regulation and Action Basic/Clinical

**Date/Time:** Friday, Mar. 6, 2015, 1-3:00 p.m.

**Location:** Hall D-F, Adrenal

**Poster:** FRI-360

**Presenter:** Stephen W. Hunt, III, Ph.D., chief scientific officer, Atterocor

**Title:** ATR-101 Phase 1 Clinical Study for Adrenocortical Carcinoma

**Session:** SAT 354-378-Adrenocortical Tumors Clinical

**Date/Time:** Saturday, Mar. 7, 2015, 1-3:00 p.m.

**Location:** Hall D-F, Adrenal

**Poster:** SAT-377

**Presenter:** Aung Naing, M.D., The University of Texas MD Anderson Cancer Center

### **About Adrenal Cancer**

Adrenal cancer is often diagnosed in the late stages of disease when there is a very poor patient prognosis. Adrenocortical carcinoma (ACC) is a cancer of the adrenal cortex that occurs when cancer cells form in the outer layer (cortex) of the adrenal gland. This form of cancer is rare, with approximately 500 to 600 patients diagnosed in the U.S. each year and around 1,000 patients in the U.S. overall. Current treatment options are often toxic, ineffective and poorly tolerated in many patients, and surgery is not a viable treatment option for the majority of ACC patients. With limited treatment options, there exists a desperate need for new therapies for adrenal cancer.

### **About Atterocor, Inc.**

Atterocor is focused on the development of ATR-101, a novel, oral drug candidate for the treatment of adrenocortical carcinoma (ACC). Founded in 2012, Atterocor is backed by \$16 million in Series A venture capital financing from top-tier life sciences investors Frazier Healthcare, Osage University Partners and 5AM Ventures, along with the Regents of the University of Michigan under the MINTS program (Michigan Investment in New Technology Startups) and The Michigan Pre-Seed Capital Fund, an MEDC program managed by Ann Arbor Spark. Atterocor is based in Ann Arbor, Michigan.

###